Common use of EFFECT OF DESIGNATION OF COLLABORATION ANTIBODIES Clause in Contracts

EFFECT OF DESIGNATION OF COLLABORATION ANTIBODIES. Any Antibody that is designated a Collaboration Antibody in accordance with Section 1.2.6 shall be exclusive to the Collaboration. Except as otherwise provided in this Agreement, once an Antibody is designated a Collaboration Antibody, * as more fully described in Section 4. 1.

EFFECT OF DESIGNATION OF COLLABORATION ANTIBODIES. Any Antibody that is designated a Collaboration Antibody in accordance with Section 1.2.6 shall be exclusive to the Collaboration. Except as otherwise provided in this Agreement, once an Antibody is designated a Collaboration Antibody, * [*] associated with the research, development and commercialization of such Antibody shall be [*], as more fully described in Section 4. 14.1.

EFFECT OF DESIGNATION OF COLLABORATION ANTIBODIES. Any Antibody that is designated a Collaboration Antibody in accordance with Section 1.2.6 shall be exclusive to the Collaboration. Except as otherwise provided in this Agreement, once an Antibody is designated a Collaboration Antibody, * all costs associated with the research, development, manufacturing and commercialization of such Antibody shall be split 50% for deCODE and 50% for Genmab/Medarex, as more fully described in Section 4. 14.1.

EFFECT OF DESIGNATION OF COLLABORATION ANTIBODIES. Any Antibody that is designated a Collaboration Antibody in accordance with Section 1.2.6 shall be exclusive to the Collaboration. Except as otherwise provided in this Agreement, once an Antibody is designated a Collaboration Antibody, * all costs associated with the research, development and commercialization of such Antibody shall be split fifty percent (50%) for Northwest and fifty percent (50%) for Medarex, as more fully described in Section 4. 14.1.